STALICLA -Robust Pipeline

ASD-Phen1 is STALICLA’s first validated patient subgroup and includes 20% of the total ASD population with a non-monogenetic cause. Further biological characterization of ASD-Phen1 revealed a specific biological profile, or “fingerprint,” of the patient subgroup that was consistent with the biological signature proposed by the DEPI platform. ASD-Phen1 was validated by a prospective observational clinical trial conducted at the Greenwood Genetic Center (SC, U.S.), and by a second ongoing prospective trial at Cincinnati Children’s Hospital (OH, U.S.). STP1 is the first tailored treatment identified by DEPI and designed to benefit ASD-Phen1.

ASD-Phen2 is STALICLA’s second patient subgroup and includes 15-20% of the total idiopathic ASD population, STALICLA has already identified a clinical Phase 2 ready compound, STP2, and is planning to enter Phase 2 clinical trial in 2022.

STALICLA has also identified 3 additional phenotypes, Phenotype 3, Phenotype 5 and Phenotype 6. These subgroups are expected to be the “high responders” to specific treatments advanced by third parties, generating new partnership opportunities for STALICLA.